Refractory Tumor, Solid Tumor
Conditions
Keywords
immunotherapy, cancer vaccine, neoantigen
Brief summary
Tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is safe and can elicites remarkable T-cell responses but mostly did not really transfer into significant clinical benefit. One possible reason is the lack of effective antigen and the immunosuppressive microenvironment. Now we are exploring another new strategy, prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGF/anti-PD-1.
Detailed description
The human immune system can recognize and destroy cancer cells but cancer cells are capable of escaping from immune system by different ways, including the PD-1/PDL-1 axis and the VEGF signaling pathway. The PD-1/PD-L1 axis represents an adaptive immune resistance mechanism exerted by tumor cells. Previous study also revealed VEGF-A could induce tumor-associated macrophages, Treg cells, and myeloid-derived suppressor cells, creating an immunosuppressive microenvironment that prevent the maturation of dendritic cells (DCs) and inhibit the activation of NK cells and T cells. Our research group already completed some early phase clinical trials of DCs-based therapy, which illustrated tumor lysate or carcinoembryonic antigen (CEA) derived DCs-based therapy is feasible and safe in patients with advanced colorectal cancer and lung cancer, respectively. However, although DCs-based therapy elicited remarkable T-cell responses but mostly did not really transfer into significant clinical benefit in previous study. One possible reason is the lack of effective antigen and the immunosuppressive microenvironment. Now we are exploring another new strategy, prediction of neoantigen for priming DCs as cell-based therapy with or without booster of anti-VEGF/anti-PD-1.
Interventions
BIOLOGICALDendritic Cell Vaccine
Approximately 1.5 x 10\^6±20% cells will be subcutaneously injected to the patient's inguinal area (either left side or right side can be injected, only one area will be injected each time) on day 1, 8, 15, 29, 85, 141, 197, 253 and 309.
DRUGLenvatinib
Lenvatinib 10mg/day on day 43-77
DRUGNivolumab
Nivolumab 3mg/kg on day 43, 57 and 71.
Sponsors
National Cheng-Kung University Hospital
National Health Research Institutes, Taiwan
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All patient will receive DCs monotherapy initially on day 1, 8, 15 and 29 as safety run-in. Safety and efficacy (1st CT evaluation) will be conducted at day 43. On the 1st CT evaluation, patient met randomization criteria and without progression disease/safety concern will be randomized to either observation or booster of lenvatinib and nivolumab during day 43 to 77.
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥20 years of age * Provide written informed consent * Histologically confirmed stage IV pancreatic cancer, liver cancer, biliary tract cancer and colorectal cancer (excluding sarcoma and neuroendocrine tumor) that refractory or intolerance to standard therapies for their condition (there is no effective treatment by investigator judgement) * Completed tumor and germline DNA and RNA sequencing and the neoantigen prediction * Patients with chronic hepatitis B is eligible if receiving anti-hepatitis B agents and the HBV DNA level \< 2000 IU/ml prior to the preparation phase. Patients with chronic hepatitis C are eligible if HCV RNA is undetectable (\<15 IU/ml) prior to the preparation phase * Adequate organ function * Absolute neutrophil count \>1000/mcL * Hemoglobin \> 8.0 g/dl * Platelet \> 50000/mcL * PT/aPTT \< 1.5 x upper limit of normal (ULN) * AST/ALT \< 3 x ULN * Bil(T) \< 1.5 x ULN * BUN/Cr \< 1.5 x ULN * Adequate immune system as defined by * IgG \> 614 mg/dl * IgM \> 53mg/dl * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 * Life expectancy at least\>12weeks * At least one measurable target lesion as defined by RECIST 1.1
Exclusion criteria
* Sarcoma、neuroendocrine tumor * Last anticancer therapy administered within 2 weeks and any AEs should be ≤ grade 2 prior to leukapheresis * Patients who cannot tolerate leukapheresis and follow-up blood sampling of 50ml at day 43, day 85 and end-of- treatment. * Any known active infection as judged by the investigator * Any known chronic active infection of HIV, HTLV-1 or HTLV-2 * Requirement of systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to the screen phase. Inhaled or topical steroids and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease. * Other immunocompromising condition that in the opinion of the treating physician renders the patient a poor candidate for this trial * Pregnant women, nursing women, men or women of childbearing potential who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device (IUD), abstinence, etc.) * Patients with history of penicillin allergy * Other medical problems or conditions that, in the opinion of the investigator, would make participation in the study hazardous for the patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects experienced limiting toxicities in the first 6 weeks. | 6 weeks | The following toxicities that happened during first 6 weeks are considered LTs. Toxicities are graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0: * \>=Grade 3 non-hematological toxicity * \>=Grade 4 hematological toxicity * Any death not clearly due to the underlying disease or extraneous causes. * Any case meeting Hy's law * Recurrent grade 2 pneumonitis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of patients who had a clinical response | 1 year | Response was assessed by the iRECIST. |
| Number of participants who did not progressed or survived at 1 year | 1 year | 1 year progression-free survival and overall survival rate |
| Number of subjects experienced any ≥ grade 3 toxicities. | 1 year | any ≥ grade 3 toxicities rate |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects experienced immune response | 1 year | The production of IFN-γ that occurs subsequent to the dendritic cells-based therapy as determined by ELISPOT Assay or Flow Cytometry Analysis. Other immune response biomarker study including but not limited to whole exome sequencing, bulk RNA sequencing and single cell RNA sequencing. |
Countries
Taiwan
Contacts
Primary ContactYung-Yeh Su, MD
Backup ContactKuan-Chung Hsiao, PhD
Outcome results
None listed